Role of periostin in evaluating the responsiveness of allergic patients to allergen-specific immunotherapy

Authors

  • Nashwa M Selim Department of Medical Microbiology and Immunology, Faculty of Medicine, Zagazig University. Shaibet and Nakareyah, City, State, Postal code, Country: Zagazig, 44519, Egypt
  • Somia El Sheikh Department of Medical Microbiology and Immunology, Faculty of Medicine, Zagazig University. Shaibet and Nakareyah, City, State, Postal code, Country: Zagazig, 44519, Egypt
  • Wafaa S Metwally Department of Medical Microbiology and Immunology, Faculty of Medicine, Zagazig University. Shaibet and Nakareyah, City, State, Postal code, Country: Zagazig, 44519, Egypt

DOI:

https://doi.org/10.3329/bjms.v21i1.56347

Keywords:

allergic rhinitis; biomarkers; periostin; sIL-2R; allergen specific immunotherapy

Abstract

Objectives: Allergen-specific immunotherapy (AIT) has been considered the most effective treatment for IgE mediated allergies, especially respiratory allergies. Several biomarkers have been developed to evaluate the clinical efficacy of AIT, yet none of them have been thoroughly validated. So our objective here is to investigate the usefulness of periostin as a biomaker for monitoring the efficacy of allergen immunotherapy.

Materials and methods: This study included 46 healthy non-atopic volunteers and 46 patients with allergic rhinitis (AR). They were sensitized only to date palm pollen. The participants were tested by skin prick test and total serum IgE levels were measured. Serum samples were collected from healthy subjects and allergic patients before and after the one-year AIT. Serum levels of periostin, eotaxin, and sIL-2R were estimated by ELISA. Symptom scores in the allergic patients were also evaluated before and after completing one year AIT.

Results: There is a significant increase in serum levels of IgE, periostin, sIL-2R, and eotaxin in allergic patients as compared to healthy controls. Symptom scores, sIL-2R and serum periostin levels were significantly decreased after one-year AIT in AR patients.

Conclusion: Periostin can be used as a biomarker to evaluate AIT efficacy in AR patients.

Bangladesh Journal of Medical Science Vol. 21(1) 2022 Page : 184-190

Downloads

Download data is not yet available.
Abstract
6
PDF
7

Downloads

Published

2022-01-01

How to Cite

Selim, N. M., Sheikh, S. E. ., & Metwally, W. S. (2022). Role of periostin in evaluating the responsiveness of allergic patients to allergen-specific immunotherapy. Bangladesh Journal of Medical Science, 21(1), 184–190. https://doi.org/10.3329/bjms.v21i1.56347

Issue

Section

Original Articles